Try our Advanced Search for more refined results

US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

March 07, 2014

In re Galena Biopharma, Inc. Derivative Litigation

Track this case

Case Number:

3:14-cv-00382

Court:

Oregon

Nature of Suit:

Stockholder's Suits

Multi Party Litigation:

Derivative Litigation

Judge:

Michael H. Simon

Firms

Companies

Sectors & Industries:

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. December 04, 2015

    Galena To Pay $20M To End Investor Suits Over Deceptive PR

    Galena Biopharma Inc. and its brass have agreed to pay $20 million to settle a securities class action and a derivative suit accusing them of inflating the company's share price with a misleading marketing campaign and committing insider trading, the pharmaceutical maker announced on Friday.

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login